Company news
BioCardia, Inc. news in 2022
BioCardia, Inc.'s news releases, calls and decks from 2022, newest first.
BioCardia Letter to Shareholders
December 21, 2022
BioCardia Announces $3.6 Million Private Placement of Common Stock
December 14, 2022
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
December 5, 2022
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
November 8, 2022
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
November 1, 2022
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting
October 2, 2022
BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
September 8, 2022
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
August 30, 2022
BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
August 23, 2022
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results
August 9, 2022
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
August 3, 2022
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
July 31, 2022
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
June 14, 2022
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results
May 10, 2022
BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022
May 3, 2022
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
April 11, 2022
BioCardia Reports 2021 Financial Results and Recent Business Highlights
March 28, 2022
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
March 21, 2022
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
February 28, 2022
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
February 13, 2022
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
February 2, 2022
BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
January 9, 2022